Latest News and Press Releases

17 February 2015 AstraZeneca today announced that Dr Cornelia (Cori) Bargmann will be proposed to shareholders for election as a Non-Executive Director at the Company's Annual General Meeting (AGM)...

AstraZeneca has announced that the US District Court for the District of New Jersey ruled US Patent No. 7,524,834 ("the '834 patent"), protecting PULMICORT RESPULES in the US, is...

AstraZeneca to acquire rights to actavis' Branded respiratory portfolio in THE US AND CANADA Agreement strengthens AstraZeneca's aclidinium respiratory franchise and adds immediate revenues with...

Det finansiella resultatet för 2014 är i linje med den höjda prognosen som lämnades i samband med resultatet för tredje kvartalet 2014. · Intäkterna för helåret ökade med 3 % i fasta valutakurser...

AstraZeneca Fourth Quarter and Full Year Results 2014 On Thursday, 5 February 2015, AstraZeneca will release fourth quarter and full year results for 2014 at 07:00GMT. An analyst presentation...

AstraZeneca today announced the European Medicines Agency has accepted the Marketing Authorisation Application (MAA) for lesinurad 200mg tablets. Lesinurad is a selective uric acid reabsorption...

PEGASUS-TIMI 54 STUDY OF BRILINTA® MEETS PRIMARY ENDPOINT IN BOTH 60MG AND 90MG DOSES Both BRILINTA 60mg and 90mg demonstrate statistically significant reduction in major cardiovascular thrombotic...

LYNPARZA™ approved by the US FOOD AND DRUG ADMINISTRATION FOR THE TREATMENT OF ADVANCED OVARIAN CANCER IN PATIENTS WITH GERMLINE BRCA-MUTATIONS AstraZeneca today announced that the US Food and Drug...

LYNPARZA™ approved IN THE EUROPEAN UNION as FIRST-IN-CLASS treatment for ADVANCED BRCA-MUTATED OVARIAN CANCER AstraZeneca today announced that the European Commission (EC) has granted Marketing...

MOVENTIG® APPROVED IN THE EUROPEAN UNION FOR OPIOID-INDUCED CONSTIPATION First in class treatment approved for adult patients with opioid-induced constipation who have had an inadequate response to...